Literature DB >> 18720513

HIV entry inhibitors and their potential in HIV therapy.

Keduo Qian1, Susan L Morris-Natschke, Kuo-Hsiung Lee.   

Abstract

This review discusses recent progress in the development of anti-HIV agents targeting the viral entry process. The three main classes (attachment inhibitors, co-receptor binding inhibitors, and fusion inhibitors) are further broken down by specific mechanism of action and structure. Many of these inhibitors are in advanced clinical trials, including the pan class="Species">HIV maturation inhibitor bevirimat, from the authors' laboratories. In addition, the CCR5 inhibitor maraviroc has recently been FDA-approved. Possible roles for these agents in anti-HIV therapy, including treatment of virus resistant to current drugs, are also discussed. (c) 2008 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18720513      PMCID: PMC3773846          DOI: 10.1002/med.20138

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  141 in total

1.  Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.

Authors:  Shinichi Imamura; Takashi Ichikawa; Youichi Nishikawa; Naoyuki Kanzaki; Katsunori Takashima; Shinichi Niwa; Yuji Iizawa; Masanori Baba; Yoshihiro Sugihara
Journal:  J Med Chem       Date:  2006-05-04       Impact factor: 7.446

2.  Interaction of small molecule inhibitors of HIV-1 entry with CCR5.

Authors:  Christoph Seibert; Weiwen Ying; Svetlana Gavrilov; Fotini Tsamis; Shawn E Kuhmann; Anandan Palani; Jayaram R Tagat; John W Clader; Stuart W McCombie; Bahige M Baroudy; Steven O Smith; Tatjana Dragic; John P Moore; Thomas P Sakmar
Journal:  Virology       Date:  2006-02-21       Impact factor: 3.616

Review 3.  Maraviroc.

Authors:  Natalie J Carter; Gillian M Keating
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys.

Authors:  T L Wallace; S A Bazemore; D J Kornbrust; P A Cossum
Journal:  J Pharmacol Exp Ther       Date:  1996-09       Impact factor: 4.030

5.  A new classification for HIV-1.

Authors:  E A Berger; R W Doms; E M Fenyö; B T Korber; D R Littman; J P Moore; Q J Sattentau; H Schuitemaker; J Sodroski; R A Weiss
Journal:  Nature       Date:  1998-01-15       Impact factor: 49.962

6.  1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity.

Authors:  J J Hale; R J Budhu; E B Holson; P E Finke; B Oates; S G Mills; M MacCoss; S L Gould; J A DeMartino; M S Springer; S Siciliano; L Malkowitz; W A Schleif; D Hazuda; M Miller; J Kessler; R Danzeisen; K Holmes; J Lineberger; A Carella; G Carver; E Emini
Journal:  Bioorg Med Chem Lett       Date:  2001-10-22       Impact factor: 2.823

7.  Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket.

Authors:  Laurie A Castonguay; Youmin Weng; William Adolfsen; Jerry Di Salvo; Ruth Kilburn; Charles G Caldwell; Bruce L Daugherty; Paul E Finke; Jeffrey J Hale; Christopher L Lynch; Sander G Mills; Malcolm MacCoss; Martin S Springer; Julie A DeMartino
Journal:  Biochemistry       Date:  2003-02-18       Impact factor: 3.162

Review 8.  Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: a pathogenesis-based perspective.

Authors:  Michael Louie; Martin Markowitz
Journal:  Antiviral Res       Date:  2002-07       Impact factor: 5.970

9.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

Authors:  C Wild; T Oas; C McDanal; D Bolognesi; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

10.  Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion.

Authors:  G B Melikyan; R M Markosyan; H Hemmati; M K Delmedico; D M Lambert; F S Cohen
Journal:  J Cell Biol       Date:  2000-10-16       Impact factor: 10.539

View more
  33 in total

Review 1.  Novel approaches in anti-arenaviral drug development.

Authors:  Andrew M Lee; Antonella Pasquato; Stefan Kunz
Journal:  Virology       Date:  2010-12-22       Impact factor: 3.616

Review 2.  Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach.

Authors:  Kuo-Hsiung Lee
Journal:  J Nat Prod       Date:  2010-03-26       Impact factor: 4.050

3.  The Effects of Statistical Multiplicity of Infection on Virus Quantification and Infectivity Assays.

Authors:  Bhaven A Mistry; Maria R D'Orsogna; Tom Chou
Journal:  Biophys J       Date:  2018-06-19       Impact factor: 4.033

4.  Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors.

Authors:  Keduo Qian; Ibrahim D Bori; Chin-Ho Chen; Li Huang; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2012-09-14       Impact factor: 7.446

5.  Short Communication: Inhibition of DC-SIGN-Mediated HIV-1 Infection by Complementary Actions of Dendritic Cell Receptor Antagonists and Env-Targeting Virus Inactivators.

Authors:  Sergey Pustylnikov; Rajnish S Dave; Zafar K Khan; Vanessa Porkolab; Adel A Rashad; Matthew Hutchinson; Frank Fieschi; Irwin Chaiken; Pooja Jain
Journal:  AIDS Res Hum Retroviruses       Date:  2015-09-18       Impact factor: 2.205

6.  Binding Site Geometry and Subdomain Valency Control Effects of Neutralizing Lectins on HIV-1 Viral Particles.

Authors:  Sabrina Lusvarghi; Katheryn Lohith; Jeanne Morin-Leisk; Rodolfo Ghirlando; Jenny E Hinshaw; Carole A Bewley
Journal:  ACS Infect Dis       Date:  2016-10-03       Impact factor: 5.084

Review 7.  Plant-derived triterpenoids and analogues as antitumor and anti-HIV agents.

Authors:  Reen-Yen Kuo; Keduo Qian; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Nat Prod Rep       Date:  2009-08-13       Impact factor: 13.423

8.  Discovery and synthesis of novel beesioside I derivatives with potent anti-HIV activity.

Authors:  Haifeng Wu; Guoxu Ma; Qinwen Yang; Yindi Zhu; Li Huang; Yu Tian; Xiaoming Yang; Menghan Zhang; Chin-Ho Chen; Susan L Morris-Natschke; Meihua Yang; Xudong Xu; Kuo-Hsiung Lee
Journal:  Eur J Med Chem       Date:  2019-01-10       Impact factor: 6.514

9.  A kinome RNAi screen identified AMPK as promoting poxvirus entry through the control of actin dynamics.

Authors:  Theresa S Moser; Russell G Jones; Craig B Thompson; Carolyn B Coyne; Sara Cherry
Journal:  PLoS Pathog       Date:  2010-06-17       Impact factor: 6.823

10.  Identification of a new region of SARS-CoV S protein critical for viral entry.

Authors:  Ying Guo; Jennifer Tisoncik; Susanna McReynolds; Michael Farzan; Bellur S Prabhakar; Thomas Gallagher; Lijun Rong; Michael Caffrey
Journal:  J Mol Biol       Date:  2009-10-21       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.